Vertex Pharmaceuticals shares closed up 1.36% at $510.08, outpacing the S&P 500's 0.6% gain. The drugmaker is scheduled to report earnings on November 2, 2026, with analysts projecting earnings of $4.84 per share, representing year-over-year growth of 0.83%, and revenue of $3.4 billion, up 10.43% from the year-ago period. For the full year, the Zacks Consensus Estimates call for earnings of $18.86 per share and revenue of $13.21 billion, changes of +2.5% and +10.09% respectively from last year. The Zacks Consensus EPS estimate has moved 1.03% lower within the past month, and Vertex Pharmaceuticals currently carries a Zacks Rank of #3 (Hold). The stock trades at a Forward P/E ratio of 26.69, a premium to its industry's average of 23.15, and has a PEG ratio of 1.95 versus the Medical - Biomedical and Genetics industry average of 1.7.
Vertex Pharmaceuticals IncShares rose 1.36% ahead of its Nov 2 earnings report, with analyst estimates and a Zacks #3 (Hold) rank cited; no company-specific development beyond the upcoming earnings and valuation context.
